Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.

Sciaraffia E, Riccomi A, Lindstedt R, Gesa V, Cirelli E, Patrizio M, De Magistris MT, Vendetti S.

J Leukoc Biol. 2014 Jul;96(1):113-22. doi: 10.1189/jlb.3A0513-302RR. Epub 2014 Mar 20.

2.

Implication of the oligomeric state of the N-terminal PTX3 domain in cumulus matrix assembly.

Ievoli E, Lindstedt R, Inforzato A, Camaioni A, Palone F, Day AJ, Mantovani A, Salvatori G, Salustri A.

Matrix Biol. 2011 Jun;30(5-6):330-7. doi: 10.1016/j.matbio.2011.05.002. Epub 2011 May 18.

3.

Therapeutic use of avidin is not hampered by antiavidin antibodies in humans.

Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE, Albertoni C, Leoni B, Rosi A, D'Alessio V, Deiana K, Paganelli G, De Santis R.

Cancer Biother Radiopharm. 2010 Oct;25(5):563-70. doi: 10.1089/cbr.2010.0797. Epub 2010 Sep 23.

PMID:
20863248
4.

Polyclonal Treg cells enhance the activity of a mucosal adjuvant.

Vendetti S, Davidson TS, Veglia F, Riccomi A, Negri DR, Lindstedt R, Pasquali P, Shevach EM, De Magistris MT.

Immunol Cell Biol. 2010 Oct;88(7):698-706. doi: 10.1038/icb.2010.76. Epub 2010 Jun 29.

PMID:
20585335
5.

The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.

Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, Rivieccio V, Briggs DC, Kadler KE, Verdoliva A, Bottazzi B, Mantovani A, Salvatori G, Day AJ.

J Biol Chem. 2010 Jun 4;285(23):17681-92. doi: 10.1074/jbc.M109.085639. Epub 2010 Apr 2.

6.

The immunosuppressor st1959, a 3,5-diaryl-s-triazole derivative, inhibits T cell activation by reducing NFAT nuclear residency.

Lindstedt R, Ruggiero V, D' Alessio V, Manganello S, Petronzelli F, Stasi MA, Vendetti S, Assandri A, Carminati P, De Santis R.

Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):29-42.

PMID:
19309550
7.

Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G, Chinol M.

Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):68-77. Epub 2006 Jun 6.

PMID:
16755333
8.

Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.

De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, Rosi A, Anastasi AM, Lindstedt R, Caroni N, Arseni B, Chiodi P, Verdoliva A, Cassani G, Chinol M, Paganelli G, Carminati P.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6.

9.

Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal anti-tenascin-C antibody by screening of a phage display library.

Bellofiore P, Petronzelli F, De Martino T, Minenkova O, Bombardi V, Anastasi AM, Lindstedt R, Felici F, De Santis R, Verdoliva A.

J Chromatogr A. 2006 Feb 24;1107(1-2):182-91. Epub 2006 Jan 18.

PMID:
16414054
10.

Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.

Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S.

Cancer. 2003 Dec 1;98(11):2430-9.

11.

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

De Santis R, Anastasi AM, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P.

Br J Cancer. 2003 Apr 7;88(7):996-1003.

12.

[Situation is under the control].

Lindstedt R.

Duodecim. 2001;117(23):2447-50. Finnish. No abstract available.

PMID:
12184104
13.

Amino acid substitutions in the putative MHC class II "dimer of dimers" interface inhibit CD4+ T cell activation.

Lindstedt R, Monk N, Lombardi G, Lechler R.

J Immunol. 2001 Jan 15;166(2):800-8.

14.

Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice.

Perraudeau M, Taylor PR, Stauss HJ, Lindstedt R, Bygrave AE, Pappin DJ, Ellmerich S, Whitten A, Rahman D, Canas B, Walport MJ, Botto M, Altmann DM.

Eur J Immunol. 2000 Oct;30(10):2871-80.

15.

Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells.

Wykes M, Poudrier J, Lindstedt R, Gray D.

Eur J Immunol. 1998 Feb;28(2):548-59.

16.

Radioiodine treatment of hyperthyroidism in a pregnant women.

Berg GE, Nyström EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Norén AH, Westphal OG.

J Nucl Med. 1998 Feb;39(2):357-61.

18.

The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif.

Lindstedt R, Liljedahl M, Péléraux A, Peterson PA, Karlsson L.

Immunity. 1995 Nov;3(5):561-72.

19.

Characterization of Pseudomonas aeruginosa-induced MDCK cell injury: glycosylation-defective host cells are resistant to bacterial killing.

Apodaca G, Bomsel M, Lindstedt R, Engel J, Frank D, Mostov KE, Wiener-Kronish J.

Infect Immun. 1995 Apr;63(4):1541-51.

20.

Strategies for studying bacterial adhesion in vivo.

Leffler H, Agace W, Hedges S, Lindstedt R, Svensson M, Svanborg C.

Methods Enzymol. 1995;253:206-20. Review. No abstract available.

PMID:
7476387
21.

Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells.

Karlsson L, Péléraux A, Lindstedt R, Liljedahl M, Peterson PA.

Science. 1994 Dec 2;266(5190):1569-73.

PMID:
7985028
22.

Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production.

Svensson M, Lindstedt R, Radin NS, Svanborg C.

Infect Immun. 1994 Oct;62(10):4404-10.

23.

Bacterial adherence and mucosal cytokine production.

Svanborg C, Agace W, Hedges S, Lindstedt R, Svensson ML.

Ann N Y Acad Sci. 1994 Aug 15;730:162-81.

PMID:
7915893
24.

Possible interaction between animal lectins and bacterial carbohydrates.

Mandrell RE, Apicella MA, Lindstedt R, Leffler H.

Methods Enzymol. 1994;236:231-54. No abstract available.

PMID:
7968613
25.

L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I.

Huflejt ME, Turck CW, Lindstedt R, Barondes SH, Leffler H.

J Biol Chem. 1993 Dec 15;268(35):26712-8.

26.
27.
28.
29.

The receptor repertoire defines the host range for attaching Escherichia coli strains that recognize globo-A.

Lindstedt R, Larson G, Falk P, Jodal U, Leffler H, Svanborg C.

Infect Immun. 1991 Mar;59(3):1086-92.

30.

Mechanism of adherence of Moraxella (Branhamella) catarrhalis.

Rikitomi N, Andersson B, Matsumoto K, Lindstedt R, Svanborg C.

Scand J Infect Dis. 1991;23(5):559-67.

PMID:
1685025
31.

Anti-adhesive activity of human casein against Streptococcus pneumoniae and Haemophilus influenzae.

Aniansson G, Andersson B, Lindstedt R, Svanborg C.

Microb Pathog. 1990 May;8(5):315-23.

PMID:
2215182
32.

Inhibition of bacterial attachment: examples from the urinary and respiratory tracts.

Svambprg Edén C, Andersson B, Aniansson G, Lindstedt R, de Man P, Nielsen A, Leffler H, Wold A.

Curr Top Microbiol Immunol. 1990;151:167-84. Review. No abstract available.

PMID:
2196162
33.

Binding specificities of wild-type and cloned Escherichia coli strains that recognize globo-A.

Lindstedt R, Baker N, Falk P, Hull R, Hull S, Karr J, Leffler H, Svanborg Edén C, Larson G.

Infect Immun. 1989 Nov;57(11):3389-94.

34.

Globo-A--a new receptor specificity for attaching Escherichia coli.

Senior D, Baker N, Cedergren B, Falk P, Larson G, Lindstedt R, Edén CS.

FEBS Lett. 1988 Sep 12;237(1-2):123-7.

Supplemental Content

Loading ...
Support Center